SVEP1 Genotype

Most heart attack risk conversations stop at cholesterol, blood pressure, and family history. But a small slice of your inherited risk lives in genes that have nothing to do with how your body handles fat, and the SVEP1 gene is one of them.

SVEP1 (Sushi, Von Willebrand factor type A, EGF and Pentraxin domain containing 1) genotyping looks at variations in a gene that helps shape the walls of your blood vessels. Certain variants quietly raise your odds of plaque building up in your arteries, and the effect appears to be largely independent of your cholesterol numbers.

What the SVEP1 Gene Does

SVEP1 codes for a protein found in the spaces between cells, where it helps build and maintain the scaffolding that holds blood vessels together. Inside atherosclerotic plaques, SVEP1 is produced by smooth muscle cells in the artery wall and by endothelial cells lining the inside of the vessel. Once released, it can drive smooth muscle cells to multiply, alter signaling pathways that control inflammation, and bind an orphan receptor called PEAR1 that activates platelets and is now thought to be a key way SVEP1 promotes vascular disease.

The picture is not entirely one-directional. While several studies point to SVEP1 as pro-atherogenic, at least one mouse study found that reducing SVEP1 actually increased plaque size, suggesting the protein may also have a protective role under some conditions. This genuine disagreement in the literature is part of why SVEP1 remains a research-grade marker rather than an established clinical tool, and why interpreting your genotype should be done with appropriate humility.

In short, this is a gene that influences how your arteries respond to wear and tear from the inside out. The variant you inherit can nudge that response toward more inflammation and more plaque, or leave it largely undisturbed.

Coronary Artery Disease Risk

The most studied SVEP1 variant is called p.D2702G, a single change in the protein's structure that about 1 in 28 people carries (a minor allele frequency of 3.60%). In a genetic analysis of more than 120,000 people in total (roughly 42,000 with coronary artery disease and 78,000 without), each copy of this variant raised the odds of coronary disease by about 14% (odds ratio 1.14).

What makes this finding stand out is what it is not driven by. The variant only raises systolic blood pressure by about 1 mmHg (0.94 mmHg per allele copy), and that small bump cannot explain the full 14% jump in coronary risk. The rest of the effect appears to come from how SVEP1 acts directly on artery walls, independent of standard risk factors like LDL cholesterol or blood pressure. The variant has no detectable association with any plasma lipid trait.

Laboratory work on human and mouse tissue helps explain why. SVEP1 inside plaques drives smooth muscle cell proliferation, disrupts cell signaling that normally keeps arteries calm, amplifies inflammation, and activates platelets through PEAR1. Carrying the p.D2702G variant appears to enhance some of these pro-plaque effects.

Blood Pressure and Hypertension

Beyond coronary disease, SVEP1 variants show modest links to blood pressure. The p.D2702G variant is associated with that small systolic bump of about 1 mmHg. A separate variant called rs7042161 has been suggestively linked to essential hypertension in health record studies, with about a 10% increase in odds (odds ratio approximately 1.1) and supportive signals from outside databases. These effects are smaller than the coronary risk signal, but they hint that SVEP1 may also nudge your blood pressure regulation.

Glaucoma in Families With Known Risk

In families that already carry mutations in another gene called TEK that causes primary congenital glaucoma (a serious eye pressure condition present from birth), a rare SVEP1 variant called p.R997C appears to make the disease worse. In one family, four of five affected individuals carried this SVEP1 variant, and they had more severe disease than relatives who did not. Lab work suggests the variant disrupts how SVEP1 supports the formation of Schlemm's canal, the drainage channel that controls eye pressure. For most people without a TEK mutation, this finding is not directly relevant. For families with known TEK disease, it is one more piece of the inheritance puzzle.

Drug Response in Liver Disease

A different SVEP1 variant, rs2991364, predicts how people with cirrhotic ascites (fluid buildup in the abdomen from advanced liver disease) respond to a medication called tolvaptan. In a Japanese cohort, carrying this variant raised the odds of being a non-responder by about 3.55 times. The original report suggested the minor allele lowers SVEP1 expression in liver and brain tissue, which may make vascular networks more fragile and contribute to poor fluid handling on the drug. This is highly specific to a clinical situation most readers will not face, but it illustrates how SVEP1 variation shapes more than just heart risk.

One Test, Lifelong Information

Your SVEP1 genotype is fixed at conception. The variants you carry today are the same ones you will carry at 80. This is a once-in-a-lifetime test. There is no value in retesting the SVEP1 result itself unless there is a question about the accuracy of the original call (for example, a low-confidence variant call from a SNP chip that warrants confirmation by a second method).

The value of this test compounds over years, not from retesting it, but from acting on it. If you carry a higher-risk variant, the data should push you toward earlier and more frequent monitoring of the markers that actually move: ApoB or LDL cholesterol every 6 to 12 months, blood pressure regularly, and inflammatory markers like hs-CRP (high-sensitivity C-reactive protein) annually. A coronary calcium scan in your 40s rather than your 60s becomes a more reasonable choice.

What to Do With an At-Risk Result

If you carry a higher-risk SVEP1 variant, the variant itself cannot be changed. But your overall heart attack risk is shaped by many factors, and most of them are modifiable. The decision pathway is about layering this result on top of everything else you know about your cardiovascular profile. No clinical guideline currently recommends a specific management algorithm based on SVEP1 status, so the steps below are reasonable preventive cardiology measures, not standard of care driven by your genotype.

• Run a full lipid workup: a basic cholesterol panel is not enough. Order ApoB (a count of the particles that drive plaque), Lp(a) (lipoprotein little-a, a separate inherited risk factor), and a particle-level NMR (nuclear magnetic resonance) lipid analysis if you want the clearest picture.
• Get a baseline calcium score earlier: a coronary calcium scan in your 40s gives you a direct look at whether plaque has actually formed, regardless of your cholesterol numbers.
• Track inflammation: hs-CRP annually helps you see whether the inflammatory environment SVEP1 acts in is being kept calm.
• Consider lipidology input: if you carry the high-risk variant and your ApoB is anywhere near the upper end of the reference range, a lipidologist or preventive cardiologist can help decide whether earlier statin or PCSK9 (proprotein convertase subtilisin/kexin type 9) therapy makes sense for you.

Why a Normal Lipid Panel Does Not Cover This

The p.D2702G variant raises coronary risk largely independent of cholesterol. That means a clean LDL number does not rule out the inherited risk this test detects. Standard lipid panels measure what is in your blood today. SVEP1 genotyping measures a constant background influence on how your artery walls behave, no matter what your lipids look like in any given month.

What This Test Cannot Tell You

SVEP1 genotyping is a research-grade marker that is not yet part of any routine clinical guideline. The 14% increase in coronary risk per copy of the p.D2702G variant is real and replicated, but it is a relatively modest effect compared to the strongest cardiovascular risk factors. Carrying a risk variant does not mean you will develop coronary disease. Not carrying it does not mean you are protected. Laboratory studies also disagree about whether SVEP1 is uniformly harmful to arteries or context-dependent. Treat the result as one input among many, useful for adjusting how aggressively you monitor and manage modifiable risk factors, not as a verdict.

When the Result Can Be Misleading

Because SVEP1 genotyping is a genetic test, the usual confounders that affect blood-based markers (recent meals, exercise, illness, time of day) do not apply. The result you get today would be the same a decade from now. But a few testing-specific issues are worth knowing about.

• Variant panel coverage: this test detects the specific SVEP1 variants the assay is designed to find. A result reported as low-risk does not rule out other rare variants in the same gene that the panel does not look for.
• Ancestry differences: the p.D2702G variant was characterized largely in European-ancestry populations, and the precise risk it carries may differ in other groups where it is rarer or more common.
• Direct-to-consumer versus clinical-grade testing: a 23andMe-style report and a clinical genotyping result may not always agree on rare variants. If a finding will drive a major medical decision, a confirmatory test by a different method is reasonable.
• Variants of uncertain significance: occasionally a sequence change is reported that has no clear clinical meaning. This does not mean you have a risk variant; it means science does not yet know what to make of it.

How Inheritance Works Here

You inherit one copy of SVEP1 from each parent. The known risk variants are reported as either heterozygous (one copy) or homozygous (two copies). For the p.D2702G variant, each copy raises coronary risk by about 14%, so two copies stack the effect. If you carry a risk variant, your biological siblings have a 50% chance of carrying it too, and each of your biological children inherits a 50% chance of getting your copy. Sharing the result with first-degree relatives lets them decide whether to test themselves.